This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Indian Pharmaceutical Market Outlook - Enhanced Purchasing Power, Rural Market Penetration And Expanded Access To Healthcare Attracting Big Pharma Investment

 

 

List of Figures

 

Figure 1: Pharmaceutical Market, India, ANDA Filings by Indian Companies, 2012 11

Figure 2: Pharmaceutical Market, India, Growth in Pharmaceutical Products Trade, (%), 2006–2011 12

Figure 3: Pharmaceutical Market, India, Population by Age Group (%), 2001–2026 13

Figure 4: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981–2009 15

Figure 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980–2009 16

Figure 6: Pharmaceutical Market, India, Life Expectancy at Birth, 1901–2025 17

Figure 7: Pharmaceutical Market, India, Healthcare Indicators in BRIC Countries, 2012 18

Figure 8: Pharmaceutical Market, India, Drivers and Barriers, 2012 19

Figure 9: Pharmaceutical Market, India, Doctors and Nurses (per 10,000 population), 2010 20

Figure 10: Pharmaceutical Market, India, SWOT Analysis 22

Figure 11: Pharmaceutical Market, India, NRHM Progress, 2011 24

Figure 12: Pharmaceutical Market, India, Intellectual Property Rights Protection Framework, 2010 25

Figure 13: Pharmaceutical Market, India, Regulatory Landscape, Intellectual Property Rights Protection, 1963–2005 26

Figure 14: Pharmaceutical Market, India, Drug Distribution System, 2012 28

Figure 15: Pharmaceutical Market, India, Healthcare Expenditure, 2009 34

Figure 16: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012 34

Figure 17: Pharmaceutical Market, India, Health Insurance Companies Landscape, 2012 36

Figure 18: Pharmaceutical Market, India, Services Outsourced in Value Chain (%), 2011 37

Figure 19: Pharmaceutical Market, India, Biotechnology Market Revenue ($m), 2003–2011 38

Figure 20: Pharmaceutical Market, India, Biotechnology Market Segmentation (%), 2011 39

Figure 21: Pharmaceutical Market, India, Market by Sub-sector (%), 2011 43

Figure 22: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007–2011 44

Figure 23: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007–2011 45

Figure 24: Pharmaceutical Market, India, Market Share by Therapy Area, 2005 and 2010 46

Figure 25: Pharmaceutical Market, India, Anti-Infectives Market Revenue ($bn), 2005–2010 47

Figure 26: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005–2010 49

Figure 27: Pharmaceutical Market, India, Gastrointestinal Market Revenue ($m), 2005–2010 51

Figure 28: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005–2010 53

Figure 29: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005–2010 55

Figure 30: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005–2010 57

Figure 31: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005–2010 59

Figure 32: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005–2010 61

Figure 33: Pharmaceutical Market, India, Number of M&A Deals, 2007–2012 63

Figure 34: Pharmaceutical Market, India, M&A Deals, Deals by Value (%), 2007–2012 64

Figure 35: Pharmaceutical Market, India, Number of Licensing Deals, 2007–2012 65

Figure 36: Pharmaceutical Market, India, Licensing Deals, Deals by Value (%), 2007–2012 65

Figure 37: Pharmaceutical Market, India, Number of Partnership Deals, 2007–2012 66

Figure 38: Pharmaceutical Market, India, Partnership Deals, Deals by Value (%), 2007–2012 66

Figure 39: Pharmaceutical Market, India, Novartis Arogya Parivar Marketing Mix, 2012 68

Figure 40: Pharmaceutical Market, India, Novartis Arogya Parivar, Factsheet, 2012 69

Figure 41: Pharmaceutical Market, India, Mankind Sales Strategies, 2012 71

 

6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs